Habsnurker schreef op 2 december 2020 21:44:
Een veelbelovende update van de CEO!
Marc Voigt: "Yeah. 2020 is almost over, not for us. We will have data, actually, middle of December, at the so-called San Antonio Breast Cancer Conference. It's among the best breast cancer conferences in the world, so a very relevant place to be. We have a spotlight presentation from our big AIPAC clinical trial, where we reported some data end of March. So, this will come in the remainder of this year, maybe the one or the other update regarding our other programs as well. And then in the next year, there's quite a lot to expect. From our partners, for instance, GlaxoSmithKline, you know that we have an exclusive worldwide licensing arrangement there, they expect clinical proof of concept in first half of 2021. We will report data from Eftilagimod, our lead program, start of new clinical trials, more data from the existing clinical trials, also we hope for updates from Novartis and also our preclinical asset IMP-761 should move forward. So, there's really a lot to expect, actually, more than we had already in 2020."
Het hele interview:
www.google.com/amp/s/www.finnewsnetwo...